Computational and Biological Evaluation of Quinazolinone Prodrug for Targeting Pancreatic Cancer

P. Pospíšil,H. Korideck,Ketai Wang,Yongliang Yang,L. Iyer,A. Kassis

DOI: https://doi.org/10.1111/j.1747-0285.2012.01350.x

2012-06-01

Abstract:Our concept of enzyme‐mediated cancer imaging and therapy aims to use radiolabeled compounds to target hydrolases over‐expressed on the extracellular surface of solid tumors. A data mining approach identified extracellular sulfatase 1 (SULF1) as an enzyme expressed on the surface of pancreatic cancer cells. We designed, synthesized, and characterized 2‐(2′‐sulfooxyphenyl)‐6‐iodo‐4‐(3H)‐quinazolinone (IQ2‐S) as well as its radioiodinated form (125IQ2‐S) as a prodrug with potential for hydrolysis by SULF1. IQ2‐S was successfully docked in silico into three enzymes – homolog of SULF1, alkaline phosphatase, and prostatic acid phosphatase. The incubation of 125IQ2‐S and 125IQ2‐P with the three enzymes in solution confirms the docking results and enzyme selectivity for the analogs. The hydrolysis of both radioactive compounds produces the water‐insoluble, fluorescent product 2‐(2′‐hydroxyphenyl)‐6‐[125I]iodo‐4‐(3H)‐quinazolinone (125IQ2‐OH). The in vitro incubation of 127IQ2‐S and 127IQ2‐P with pancreatic, ovarian, and prostate cancer cells expressing studied hydrolases also results in their hydrolysis and the precipitation of 127IQ2‐OH fluorescent crystals on the cell surface. To our knowledge, these findings are the first to report the targeting of a radioactive substrate to SULF1 and that this prodrug may be potentially useful in the imaging (123I/124I/131I) and radiotherapy (131I) of pancreatic cancer.